In our study, we could not demonstrate that DPP4 inhibitors have significant action on platelet reactivity in patients with type 2 diabetes hospitalized for acute myocardial infarction using DAPT at 4 days after randomization (primary endpoint) or at 30 days (secondary endpoint). The gene discussed is DPP4; the disease is acute myocardial infarction.